4//SEC Filing
Kraus Stephen 4
Accession 0001193125-25-232234
CIK 0001671284other
Filed
Oct 5, 8:00 PM ET
Accepted
Oct 6, 7:35 PM ET
Size
13.5 KB
Accession
0001193125-25-232234
Insider Transaction Report
Form 4
NeueHealth, Inc.NEUE
Kraus Stephen
Director
Transactions
- Disposition to Issuer
Common Stock
2025-10-02−0→ 0 total(indirect: See footnote) - Disposition to Issuer
Series B Convertible Perpetual Preferred Stock
2025-10-02−0→ 0 total(indirect: See footnote)→ Common Stock (0 underlying) - Disposition to Issuer
Common Stock
2025-10-02−16,443→ 0 total
Footnotes (7)
- [F1]On October 2, 2025, NH Holdings 2025, Inc. ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.
- [F2]Pursuant to the Rollover Agreement, dated as of December 23, 2024 (the "Rollover Agreement "), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one-for-one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
- [F3]Bessemer Venture Partners IX L.P. ("Bessemer IX"), Bessemer Venture Partners IX Parallel L.P. ("Bessemer IX Parallel"), Bessemer Venture Partners IX Institutional L.P. ("Bessemer Institutional, and together with Bessemer IX, and Bessemer IX Parallel, the "Bessemer IX Funds"), Bessemer Venture Partners Century Fund L.P. ("Bessemer Century"), Bessemer Venture Partners Century Fund Parallel L.P. ("Bessemer Century Parallel") Bessemer Venture Partners Century Fund Institutional L.P. ("Bessemer Century Institutional", and together with Bessemer Century, and Bessemer Century Parallel, the "Bessemer Century Funds") and 15 Angels II LLC ("15 Angels") contributed 22,203 shares of Common Stock and 189 shares of Series B Preferred Stock; 426,445 shares of Common Stoick and 3,628 shares of Series B Preferred Stock, 359,437 shares of
- [F4](Continued from footnote 3) Common Stock and 3,058 share of Series B Preferred Stock, 7,803 shares of Common Stock and 66 shares of Series B Preferred Stock, 18,326 shares of Common Stock and 156 shares of Series B Preferred Stock, 164,872 shares of Common Stock and 1,402 shares of Series B Preferred Stock, 132 shares of Common Stocka and 1 share of Series B Preferred Stock, respectively.
- [F5]The Issuer's Series B Preferred Stock was convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the HSR Act) into the number of shares of the Issuer's common stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash ("compounded dividends")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments.
- [F6]The Series B Preferred Stock had no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock was greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provided notice of its election to convert, the Issuer may have elected to convert all of the Series B Preferred Stock into the relevant number of shares of Issuer common stock. [Continued on Note 7]
- [F7][Continuation of Note 6] At any time following the fifth anniversary of the original issuance date, the Issuer may have redeemed all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurred at any time on or after the seventh anniversary of the original issuance date.
Documents
Issuer
NeueHealth, Inc.
CIK 0001671284
Entity typeother
Related Parties
1- filerCIK 0001362099
Filing Metadata
- Form type
- 4
- Filed
- Oct 5, 8:00 PM ET
- Accepted
- Oct 6, 7:35 PM ET
- Size
- 13.5 KB